Arizona Governor Signs EO Joining ArrayRx Program

September 9, 2025

EGWP marketplace medicaid Medicare

Gov. Katie Hobbs (D) signed an executive order to join ArrayRx, a multi-state public pharmacy collaborative that offers patients discounts on prescription drugs. Arizona joins a consortium of five other states participating in the ArrayRx PBM platform and related pharmacy savings programs.

According to the governor, this action will strengthen the state’s negotiating power and demonstrate the state’s commitment to create people-centered solutions to address the high drug costs. Arizonans who use the discount card program will be able to lower the cost of their prescription drugs by up to 80% on generic drugs and 18% on some brand-name drugs.

The uninsured and residents with high-deductible health plans are expected to benefit most from the savings.

legislation

Virginia and Hawaii Introduce PDAB Legislation

The Virginia Senate introduced a bill to establish a Prescription Drug Affordability Board (PDAB) to review drugs with a wholesale acquisition cost (WAC) of $60,000 or more per year or a WAC increase of $3,000 or more in any 12-month period. For drugs deemed to cause an affordability challenge, the legislation authorizes the PDAB to […]
read more >

February 12, 2026

EGWP marketplace medicaid Medicare

Solutions

AHIP Shares Update on Plan Progress to Simplify Prior Authorization

AHIP shared progress on the voluntary, multi-year commitments made by AHIP, BCBSA, and leading health plans (including Cigna Healthcare) to streamline and simplify prior authorization. Health plans serving nearly 270 million Americans are participating in this initiative. The 2026 commitments took effect on Jan. 1 and include: reducing the scope of claims subject to prior […]
read more >

February 12, 2026

EGWP marketplace medicaid Medicare

legislation

DOL Issues Proposed Rule on Improving Transparency into PBM Fees

Pursuant to President Trump’s Executive Order “Lowering Drug Prices by Once Again Putting Americans First,” the Department of Labor’s (DOL’s) Employee Benefits Security Administration (EBSA) issued a proposed rule that would require providers of PBM services and affiliated entities of brokerage and consulting services to disclose direct and indirect compensation to their self-funded ERISA fiduciary […]
read more >

February 12, 2026

EGWP marketplace medicaid Medicare

You may also like

legislation

Virginia and Hawaii Introduce PDAB Legislation

The Virginia Senate introduced a bill to establish a Prescription Drug Affordability Board (PDAB) to review drugs with a wholesale acquisition cost (WAC) of $60,000 or more per year or a WAC increase of $3,000 or more in any 12-month period. For drugs deemed to cause an affordability challenge, the legislation authorizes the PDAB to […]
read more >

February 12, 2026

EGWP marketplace medicaid Medicare

legislation

DOL Issues Proposed Rule on Improving Transparency into PBM Fees

Pursuant to President Trump’s Executive Order “Lowering Drug Prices by Once Again Putting Americans First,” the Department of Labor’s (DOL’s) Employee Benefits Security Administration (EBSA) issued a proposed rule that would require providers of PBM services and affiliated entities of brokerage and consulting services to disclose direct and indirect compensation to their self-funded ERISA fiduciary […]
read more >

February 12, 2026

EGWP marketplace medicaid Medicare

legislation

CMS Releases 2027 Advance MA and Part D Rate Notice

On Jan. 26, the Centers for Medicare & Medicaid Services (CMS) released the CY2027 Medicare Advantage (MA) and Part D Advance Notice which provides preliminary estimates of payment changes in county benchmarks and proposes additional policies for the upcoming contract year. CMS projects a net average year-over-year payment increase of 0.09% (essentially flat) – a […]
read more >

February 12, 2026

Medicare

legislation

CMS Announces Selection of Drugs for Third Cycle of the Medicare Drug Price Negotiation Program

On Jan. 27, CMS announced the 15 drugs selected for the third cycle of negotiations under the Medicare Drug Price Negotiation Program. This is the first negotiation cycle for which Part B drugs were eligible to be selected in addition to Part D drugs. The drugs selected treat conditions such as asthma, Type-2 diabetes, arthritis, […]
read more >

February 12, 2026

Medicare

legislation

CMMI Introduces New Drug Pricing and Chronic Care Models

Since late December, the Center for Medicare and Medicaid Innovation (CMMI) has announced four new drug pricing and chronic care models: Global Benchmark for Efficient Drug Pricing (GLOBE); Guarding U.S. Medicare Against Rising Drug Costs (GUARD); Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model; and the Advancing Chronic Care with Effective, Scalable […]
read more >

February 12, 2026

EGWP medicaid Medicare